Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ABAX --- lots of upside -- Ignore unavailable to you. Want to Upgrade?

To: David Bogdanoff who wrote (416)	4/3/1998 6:56:00 AM
From: Yo Yo	Respond to of 492

David, Per my conversation with CEO of Hemagen (HMGN) a while back, the machine has been around for about 12 years. About 80% of the current installations are in the Human Medicine market. He mentioned that both the ABAX and Dade-Behring units are of the same origin. I believe he meant that people once worked together, one group split off and became ABAX (I have to verify this). If you look in HMGN's press release, their push is to develop more tests for the human market. He said disks were priced at $8. They are currently doing about $8MM per year in revenues with the machine. I would be curious what ABAX management thinks of the Dade-Behring unit. Yo Yo